AAVantgarde shared an update on its gene therapy trial for Usher syndrome type 1B at a major eye conference in October.

AAVantgarde is working on a new gene therapy and has launched a clinical trial for people living with Usher syndrome type 1B.

In late 2024, AAVantgarde shared exciting announcements on the first participant dosage, Orphan Drug Designation, and early safety data in the Phase 1/2 LUCE-1 clinical trial for vision loss caused by Usher syndrome type 1B.

MYO7A is a large gene that encodes myosin VIIA, a protein that helps maintain stereocilia in the inner ear and the retinal pigment epithelium in the retina.